Show simple item record

dc.contributor.authorAntolin, AA
dc.contributor.authorWorkman, P
dc.contributor.authorMestres, J
dc.contributor.authorAl-Lazikani, B
dc.date.accessioned2017-11-29T11:52:47Z
dc.date.issued2016-01
dc.identifier.citationCurrent pharmaceutical design, 2016, 22 (46), pp. 6935 - 6945
dc.identifier.issn1381-6128
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/958
dc.identifier.eissn1873-4286
dc.identifier.doi10.2174/1381612822666160923115828
dc.description.abstractOver the past decade, a more comprehensive, large-scale approach to studying cancer genetics and biology has revealed the challenges of tumor heterogeneity, adaption, evolution and drug resistance, while systems-based pharmacology and chemical biology strategies have uncovered a much more complex interaction between drugs and the human proteome than was previously anticipated. In this mini-review we assess the progress and potential of drug polypharmacology in biomarker-driven precision oncology. Polypharmacology not only provides great opportunities for drug repurposing to exploit off-target effects in a new single-target indication but through simultaneous blockade of multiple targets or pathways offers exciting opportunities to slow, overcome or even prevent inherent or adaptive drug resistance. We highlight the many challenges associated with exploiting known or desired polypharmacology in drug design and development, and assess computational and experimental methods to uncover unknown polypharmacology. A comprehensive understanding of the intricate links between polypharmacology, efficacy and safety is urgently needed if we are to tackle the enduring challenge of cancer drug resistance and to fully exploit polypharmacology for the ultimate benefit of cancer patients.
dc.formatPrint
dc.format.extent6935 - 6945
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectAntineoplastic Agents
dc.subjectMedical Oncology
dc.subjectDrug Resistance, Neoplasm
dc.subjectDrug Repositioning
dc.subjectPolypharmacology
dc.titlePolypharmacology in Precision Oncology: Current Applications and Future Prospects.
dc.typeJournal Article
dcterms.dateAccepted2016-09-19
rioxxterms.versionofrecord10.2174/1381612822666160923115828
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2016-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent pharmaceutical design
pubs.issue46
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.publication-statusPublished
pubs.volume22
pubs.embargo.termsNo embargo
icr.researchteamComputational Biology and Chemogenomicsen_US
dc.contributor.icrauthorAl-Lazikani, Bissanen
dc.contributor.icrauthorWorkman, Paulen
dc.contributor.icrauthorAntolin Hernandez, Alberten


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0